An updated patent review of GLP-1 receptor agonists (2020-present)

References

• Finkelstein EA, Khavjou OA, Thompson H, et al. Obesity and severe obesity forecasts through 2030. Am J Preventive Med. 2012;42(6):563–570. doi: 10.1016/j.amepre.2011.10.026
   PubMed Web of Science ®Google Scholar
• Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288–298. doi: 10.1038/s41574-019-0176-8
   PubMed Web of Science ®Google Scholar
• Morieri ML, Raz I, Consoli A, et al. Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study. J Endocrinol Invest. 2023 Jul;46(7):1429–1439. doi: 10.1007/s40618-022-02002-2
   PubMed Web of Science ®Google Scholar
• Lazzaroni E, Ben Nasr M, Loretelli C, et al. Anti-diabetic drugs and weight loss in patients with type 2 diabetes. Pharmacol Res. 2021 Sep;171:105782.
   PubMed Web of Science ®Google Scholar
• Hope DC, Vincent ML, Tan TM. Striking the balance: GLP-1/glucagon co-agonism as a treatment strategy for obesity. Front Endocrinol. 2021;12:735019. doi: 10.3389/fendo.2021.735019
   PubMed Web of Science ®Google Scholar
• Maciejewski ML, Arterburn DE, Van Scoyoc L, et al. Bariatric surgery and long-term durability of weight loss. JAMA Surgery. 2016;151(11):1046–1055. doi: 10.1001/jamasurg.2016.2317
   PubMed Web of Science ®Google Scholar
• Müller TD, Finan B, Bloom S, et al. Glucagon-like peptide 1 (GLP-1). Mol Metabol. 2019;30:72–130. doi: 10.1016/j.molmet.2019.09.010
   PubMed Web of Science ®Google Scholar
• Bendotti G, Montefusco L, Lunati ME, et al. The anti-inflammatory and immunological properties of GLP-1 receptor agonists. Pharmacol Res. 2022 Aug;182:106320. doi: 10.1016/j.phrs.2022.106320
   PubMed Web of Science ®Google Scholar
• Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728–742. doi: 10.1038/nrendo.2012.140
   PubMed Web of Science ®Google Scholar
• Williams DM, Nawaz A, Evans M. Drug therapy in obesity: a review of current and emerging treatments. Diabetes Therapy. 2020;11(6):1199–1216. doi: 10.1007/s13300-020-00816-y
   PubMed Web of Science ®Google Scholar
• Knerr PJ, Mowery SA, Douros JD, et al. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Mol Metabol. 2022;63:101533. doi: 10.1016/j.molmet.2022.101533
   PubMed Web of Science ®Google Scholar
• Bain EK, Bain SC. Recent developments in GLP-1RA therapy: a review of the latest evidence of efficacy and safety and differences within the class. Diab Obes Metab. 2021;23(Suppl 3):30–39. doi: 10.1111/dom.14487
   PubMedGoogle Scholar
• Farr OM, Sofopoulos M, Tsoukas MA, et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia. 2016;59(5):954–965. doi: 10.1007/s00125-016-3874-y
   PubMed Web of Science ®Google Scholar
• Coveleskie K, Kilpatrick LA, Gupta A, et al. The effect of the GLP‐1 analogue exenatide on functional connectivity within an NTS‐based network in women with and without obesity. Obesity Sci Prac. 2017;3(4):434–445. doi: 10.1002/osp4.124
   PubMedGoogle Scholar
• Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473–4488. doi: 10.1172/JCI75276
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obesity Metab. 2018;20(S1):5–21. doi: 10.1111/dom.13129
   PubMed Web of Science ®Google Scholar
• Suzuki R, Brown GA, Christopher JA, et al. Recent developments in therapeutic peptides for the glucagon-like peptide 1 and 2 receptors. J Med Chem. 2019;63(3):905–927. doi: 10.1021/acs.jmedchem.9b00835
   PubMed Web of Science ®Google Scholar
• Berra CC, Rossi MC, Mirani M, et al. Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: a retrospective, cohort study (sema-MiDiab01). Front Endocrinol. 2022;13:1099451. doi: 10.3389/fendo.2022.1099451
   PubMed Web of Science ®Google Scholar
• Sforza A, Vigorelli V, Rurali E, et al. Liraglutide preserves CD34(+) stem cells from dysfunction induced by high glucose exposure. Cardiovasc Diabetol. 2022 Apr 9;21(1):51. doi: 10.1186/s12933-022-01486-9
   PubMed Web of Science ®Google Scholar
• Fiorentino TV, Casiraghi F, Davalli AM, et al. Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon Papio hamadryas. JCI Insight. 2019 Oct 17;4(20). doi: 10.1172/jci.insight.93091
   PubMed Web of Science ®Google Scholar
• Mehta A, Marso SP, Neeland I. Liraglutide for weight management: a critical review of the evidence. Obesity Sci Prac. 2017;3(1):3–14. doi: 10.1002/osp4.84
   PubMedGoogle Scholar
• Wilding JP, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi: 10.1056/NEJMoa2032183
   PubMed Web of Science ®Google Scholar
• Bettge K, Kahle M, Abd El Aziz MS, et al. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obesity Metab. 2017;19(3):336–347. doi: 10.1111/dom.12824
   PubMed Web of Science ®Google Scholar
• Raccah D. Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues. Expert Opin Drug Saf. 2017;16(2):227–236. doi: 10.1080/14740338.2017.1268598
   PubMed Web of Science ®Google Scholar
• Frías JP, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2· 0 mg versus 1· 0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol. 2021;9(9):563–574. doi: 10.1016/S2213-8587(21)00174-1
   PubMed Web of Science ®Google Scholar
• Grönroos S, Helmiö M, Juuti A, et al. Effect of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric Bypass on weight loss and quality of life at 7 years in patients with morbid obesity: the SLEEVEPASS randomized clinical trial. JAMA Surg. 2021 Feb 1;156(2):137–146. doi: 10.1001/jamasurg.2020.5666
   PubMed Web of Science ®Google Scholar
• Kheirvari M, Dadkhah Nikroo N, Jaafarinejad H, et al. The advantages and disadvantages of sleeve gastrectomy; clinical laboratory to bedside review. Heliyon. 2020 Feb;6(2):e03496. doi: 10.1016/j.heliyon.2020.e03496
   PubMed Web of Science ®Google Scholar
• Clemmensen C, Finan B, Mueller TD, et al. Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases. Nat Rev Endocrinol. 2019;15(2):90–104. doi: 10.1038/s41574-018-0118-x
   PubMed Web of Science ®Google Scholar
• Kruse T, Hansen JL, Dahl K, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021 Aug 12;64(15):11183–11194. doi: 10.1021/acs.jmedchem.1c00565
   PubMed Web of Science ®Google Scholar
• Muller TD, Bluher M, Tschop MH, et al. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022 Mar;21(3):201–223. doi: 10.1038/s41573-021-00337-8
   PubMed Web of Science ®Google Scholar
• Heise T, Mari A, DeVries JH, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022;10(6):418–429. doi: 10.1016/S2213-8587(22)00085-7
   PubMed Web of Science ®Google Scholar
• Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–515. doi: 10.1056/NEJMoa2107519
   PubMed Web of Science ®Google Scholar
• Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2· 4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736–1748. doi: 10.1016/S0140-6736(21)00845-X
   PubMed Web of Science ®Google Scholar
• Becerril S, Frühbeck G. Cagrilintide plus semaglutide for obesity management. Lancet. 2021;397(10286):1687–1689. doi: 10.1016/S0140-6736(21)00944-2
   PubMed Web of Science ®Google Scholar
• Alavi SE, Cabot PJ, Moyle PM. Glucagon-like peptide-1 receptor agonists and strategies to improve their efficiency. Mol Pharm. 2019 Jun 3;16(6):2278–2295. doi: 10.1021/acs.molpharmaceut.9b00308.
   PubMedGoogle Scholar
• Sun Pharmaceutical Industry Ltd. Novel GLP-1 analogues. CN112236444A. 2021.
   Google Scholar
• Beijing Huizhi Biotechnology Co., Ltd. Long-acting GLP-1 derivative CN114621339A. 2022.
   Google Scholar
• Novartis Ag. Glucagon like peptide compounds. WO2022224164. 2022.
   Google Scholar
• Nanjing Fengjing Biopharmaceutical Technology Co., Ltd. Molecular modification of GLP-1R activator, and application of dimer of GLP-1R activator in treatment of metabolic diseases. CN111410686A. 2021.
   Google Scholar
• Nanjing Fengjing Biomedical Technology Co., Ltd. Molecular allosteric structure of GIP-Exendin-4 chimeric peptide, and application of dimer of GIP-Exendin-4 chimeric peptide in treatment of diabetes CN113493504A. 2021.
   Google Scholar
• Transtech Pharma, Inc. Oxadiazoanthracene compounds for the treatment of diabetes WO2009111700. 2009.
   Google Scholar
• Transtech Pharma, Inc. Substituted azoanthracene derivatives, Pharmaceutical compositions, and methods of use thereof WO2010114824. 2010.
   Google Scholar
• Su H, He M, Li H, et al. Boc5, a non-peptidic glucagon-like peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice. PLoS One. 2008 Aug 6;3(8):e2892. doi: 10.1371/journal.pone.0002892
   PubMed Web of Science ®Google Scholar
• Pratt E, Ma X, Liu R, et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Diabetes Obesity Metab. 2023;25(9):2634–2641. doi: 10.1111/dom.15184
   PubMed Web of Science ®Google Scholar
• Griffith DA, Edmonds DJ, Fortin JP, et al. A small-molecule oral agonist of the human glucagon-like peptide-1 receptor. J Med Chem. 2022 Jun 23;65(12):8208–8226. doi: 10.1021/acs.jmedchem.1c01856
   PubMed Web of Science ®Google Scholar
• Saxena AR, Gorman DN, Esquejo RM, et al. Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial. Nat Med. 2021 Jun;27(6):1079–1087. doi: 10.1038/s41591-021-01391-w
   PubMed Web of Science ®Google Scholar
• Kobilka BK, Deupi X. Conformational complexity of G-protein-coupled receptors. Trends Pharmacol Sci. 2007 Aug;28(8):397–406. doi: 10.1016/j.tips.2007.06.003
   PubMed Web of Science ®Google Scholar
• Pfizer Inc. GLP-1 receptor agonists and uses thereof. WO2018109607. 2018.
   Google Scholar
• Pfizer Inc. GLP-1 receptor agonists and uses thereof. WO2019239371. 2019.
   Google Scholar
• Pfizer Inc. Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt. WO2021116874. 2021.
   Google Scholar
• Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof. WO2020207474. 2020.
   Google Scholar
• GLP-1R Agonists And Uses Thereof. WO2020103815. 2020.
   Google Scholar
• Gilead Sciences, Inc. GLP-1R modulating compounds. WO2021081207. 2021.
   Google Scholar
• Shanxi Medical University. Micromolecular GLP-1R agonist and application thereof. CN111548311A. 2020.
   Google Scholar
• Shanxi Medical University. Anethomycin derivative and application of anethomycin and anethomycin derivative as GLP-1R agonist. CN114790160A. 2022.
   Google Scholar
• Xi’an Jiaotong University. Application of GLP-1R micromolecule agonist in diabetes and related complications and medicine. CN114848825A. 2022.
   Google Scholar
• Shanghai Jiaotong University. Triazole compound and application thereof. CN115536638A. 2022.
   Google Scholar
• Gilead Sciences, Inc. GLP -1R modulating compounds US20220298148. 2022.
   Google Scholar
• Ildong Pharmaceutical Co., Ltd. GLP-1 receptor agonist and use thereof. WO2021096304. 2021.
   Google Scholar
• Shenzhen Salubris Pharmaceuticals Co.ltd. Benzimidazole derivative, and preparation method therefor, and Medical use thereof. WO2022068772. 2022.
   Google Scholar
• Shenzhen Salubris Pharmaceuticals Co., Ltd. Benzimidazole derivative and preparation method therefor and Medical use thereof. WO2022111624. 2022.
   Google Scholar
• Novartis Ag. 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity. WO2022219495. 2022.
   Google Scholar
• Eli Lilly and Company.Macrocyclic glucagon-like peptide 1 receptor agonists WO2022246019. 2022.
   Google Scholar
• Salubris Pharmaceuticals Co., Ltd. Salt of GLP-1R agonist compound, and preparation method therefor and pharmaceutical use thereof. WO2023011395. 2023.
   Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007 May;132(6):2131–2157. doi: 10.1053/j.gastro.2007.03.054
   PubMed Web of Science ®Google Scholar
• Seino Y, Yamazaki Y. Roles of glucose-dependent insulinotropic polypeptide in diet-induced obesity. J Diabetes Investig. 2022 Jul;13(7):1122–1128. doi: 10.1111/jdi.13816
   PubMed Web of Science ®Google Scholar
• FDA approves novel, dual-targeted treatment for type 2 diabetes: U.S. Food And Durg Administration. 2022 [updated May 13]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes
   Google Scholar
• Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metabol. 2018;18:3–14. doi: 10.1016/j.molmet.2018.09.009
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company. GIP/GLP-1 Co-agonist compounds. WO2021150673. 2021.
   Google Scholar
• J.Co-agonists at GLP-1 and gip receptors suitable for oral delivery WO2022018186. 2022.
   Google Scholar
• Jepsen MM, Christensen MB. Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opin Emerg Drugs. 2021 Sep;26(3):231–243. doi: 10.1080/14728214.2021.1947240
   PubMed Web of Science ®Google Scholar
• Brightgene Bio-medical Technology Co., Ltd. Dual-receptor agonist of GIP and GLP-1, pharmaceutical composition and application. CN115124602A. 2022.
   Google Scholar
• China Pharmaceutical University. GLP-1R/GIPR dual-target agonist fusion protein as well as preparation method and application thereof. CN113150172A. 2021.
   Google Scholar
• Beijing Tuo Jie Biopharmaceutical Co. Ltd. Dual-agonist compound for both GLP-1 and GIP receptors and application thereof. WO2021239082. 2021.
   Google Scholar
• Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Multi-receptor agonist and medical use thereof. WO2020207477. 2020.
   Google Scholar
• Sun Pharmaceutical Industries Limited. Long acting GLP-1/GIP dual agonists WO2021260530. 2021.
   Google Scholar
• Sun Pharmaceutical Industries Limited. GLP-1/GIP dual agonists. WO2022079639. 2022.
   Google Scholar
• Eli Lilly and Company. GIP/GLP-1 co-agonist compounds. WO2020023386. 2020.
   Google Scholar
• Shanghai Hansoh Biomedical Co., Ltd. GLP-1 and GIP Co-agonist compound. CN111825758A. 2020.
   Google Scholar
• Ravn P, Madhurantakam C, Kunze S, et al. Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor. J Biol Chem. 2013 Jul 5;288(27):19760–19772. doi: 10.1074/jbc.M112.426288
   PubMed Web of Science ®Google Scholar
• Gmax Biopharm Llc. GIPR antibody, fused protein of GIPR antibody and GLP-1, pharmaceutical composition of GIPR antibody and application of pharmaceutical composition. CN112521501A. 2021.
   Google Scholar
• Day JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009 Oct;5(10):749–757. doi: 10.1038/nchembio.209
   PubMed Web of Science ®Google Scholar
• Habegger KM, Heppner KM, Geary N, et al. The metabolic actions of glucagon revisited. Nat Rev Endocrinol. 2010 Dec;6(12):689–697. doi: 10.1038/nrendo.2010.187
   PubMed Web of Science ®Google Scholar
• Jiang H, Pang S, Zhang Y, et al. A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nat Commun. 2022 Jun 24;13(1):3613. doi: 10.1038/s41467-022-31328-x
   PubMed Web of Science ®Google Scholar
• Zeigerer A, Sekar R, Kleinert M, et al. Glucagon’s metabolic action in health and disease. Compr Physiol. 2021 Apr 1;11(2):1759–1783.
   PubMed Web of Science ®Google Scholar
• Pocai A, Carrington PE, Adams JR, et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes. 2009 Oct;58(10):2258–2266. doi: 10.2337/db09-0278
   PubMed Web of Science ®Google Scholar
• Liu C, Zou Y, Qian H. GLP-1R agonists for the treatment of obesity: a patent review (2015-present). Expert Opin Ther Pat. 2020 Oct;30(10):781–794. doi: 10.1080/13543776.2020.1811851
   PubMed Web of Science ®Google Scholar
• Dong A St Co Ltd. Acylated oxyntomodulin peptide analog. CN111094331A. 2020.
   Google Scholar
• Dong-A St Co., Ltd. Long-acting glp-1 and glucagon receptor dual agonist. WO2021221359. 2021.
   Google Scholar
• Hangzhou Heze Pharmaceutical Technology Co., Ltd. Glucagon analogue, and preparation method and application thereof. CN111349155A. 2020.
   Google Scholar
• Dongguan Yunjing Biotechnology Co., Ltd. GLP-1/glucagon dual agonist fusion protein. CN113292646A. 2021.
   Google Scholar
• Shenzhen Turier Biotech development Co., Ltd. Synthesis method of GCGR/GLP-1R double-target agonist polypeptide. CN114790236A. 2022.
   Google Scholar
• Shenzhen Turier Biotech. Co., Ltd. GLP-1R/GCGR dual-target agonist peptide derivatives for treatment of viral hepatitis-related hepatic fibrosis WO2022061924. 2022.
   Google Scholar
• Ji L, Gao L, Jiang H, et al. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine. 2022 Dec;54:101691.
   PubMedGoogle Scholar
• Zimmermann T, Thomas L, Baader-Pagler T, et al. BI 456906: discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metabol. 2022;66:101633. doi: 10.1016/j.molmet.2022.101633
   PubMed Web of Science ®Google Scholar
• Klein S, Nestor JJ, Harris MS, et al. 334-OR: pemvidutide (ALT-801), a balanced (1: 1) GLP-1/glucagon dual receptor agonist, induces rapid and marked weight loss without the need for dose titration in people with overweight/obesity. Diabetes. 2022;71(Supplement_1):334–OR. doi: 10.2337/db22-334-OR
   Google Scholar
• Bhat VK, Kerr BD, Vasu S, et al. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice. Diabetologia. 2013 Jun;56(6):1417–1424. doi: 10.1007/s00125-013-2892-2
   PubMed Web of Science ®Google Scholar
• Bhat VK, Kerr BD, Flatt PR, et al. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties. Biochem Pharmacol. 2013 Jun 1;85(11):1655–1662. doi: 10.1016/j.bcp.2013.03.009
   PubMed Web of Science ®Google Scholar
• Gault VA, Bhat VK, Irwin N, et al. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice. J Biol Chem. 2013 Dec 6;288(49):35581–35591. doi: 10.1074/jbc.M113.512046
   PubMed Web of Science ®Google Scholar
• Bossart M, Wagner M, Elvert R, et al. Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. Cell Metab. 2022 Jan 4;34(1):59–74 e10. doi: 10.1016/j.cmet.2021.12.005
   PubMed Web of Science ®Google Scholar
• Eli Lilly And Company. An Incretin analog for use in glycemic control and weight management. WO2022271767. 2022.
   Google Scholar
• Wanxin Pharmaceutical Technology (suzhou) Co., Ltd. Triple agonist of glucagon-like peptide-1 receptor, glucagon receptor and gastric inhibitory peptide receptor. CN111040022A. 2020.
   Google Scholar
• Hanmi Pharm. Co., Ltd. Therapeutic use, for liver disease, of triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors, or conjugate thereof. WO2020263063. 2020.
   Google Scholar
• Zhejiang Doer Biologics Corporation. Incretin analogue, and preparation method and application thereof. CN113493503A. 2021.
   Google Scholar
• Shenzhen Deeply-invasive Biopharmaceutical Co., Ltd. GLP-1R/GCGR/GIPR triple receptor agonist and application thereof. CN114437181A. 2022.
   Google Scholar
• Eli Lilly and Company. Incretin analogs and uses thereof. WO2021126695. 2021.
   Google Scholar
• The United Bio-technology (Hengqin) Co., Ltd. Multi-agonist and use thereof. WO2022247701. 2022.
   Google Scholar
• Sunshine Lake Pharma Co., Ltd.Triple agonist for GLP-1, GCG and GIP r eceptors. WO2022268029. 2022.
   Google Scholar
• Hanmi Pharm.Co., Ltd. Pharmaceutical composition comprising glucagon/GLP-1/GIP triple agonist or long-acting conjugate thereof for preventing or treating lupus-related diseases. WO2022080989. 202 Apr 21.
   Google Scholar
• Jiangsu Chinese New Medicine Co., Ltd. GLP-1, GIP and GCG multiple receptor agonist proteins. CN114621327A. 2022.
   Google Scholar
• Zhuhai United Pharmaceutical Co., Ltd. Polypeptide compound and use thereof. CN114981295A. 2022.
   Google Scholar
• Brubaker PL. Glucagon-like peptide-2 and the regulation of intestinal growth and function. Compr Physiol. 2018 Jun 18;8(3):1185–1210.
   PubMed Web of Science ®Google Scholar
• Sigalet DL. Advances in glucagon like peptide-2 therapy. physiology, current indications and future directions. Semin Pediatr Surg. 2018 Aug;27(4):237–241. doi: 10.1053/j.sempedsurg.2018.07.008
   PubMed Web of Science ®Google Scholar
• Kim ES, Keam SJ. Teduglutide: a review in short bowel syndrome. Drugs. 2017 Mar;77(3):345–352. doi: 10.1007/s40265-017-0703-7
   PubMed Web of Science ®Google Scholar
• Kim ER, Park JS, Kim JH, et al. A GLP-1/GLP-2 receptor dual agonist to treat NASH: targeting the gut-liver axis and microbiome. Hepatology. 2022 Jun;75(6):1523–1538. doi: 10.1002/hep.32235
   PubMed Web of Science ®Google Scholar
• Madsen MSA, Holm JB, Palleja A, et al. Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice. Sci Rep. 2019 Oct 30;9(1):15582. doi: 10.1038/s41598-019-52103-x
   PubMedGoogle Scholar
• Reiner J, Berlin P, Held J, et al. Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel. JPEN J Parenter Enteral Nutr. 2022 Jul;46(5):1107–1118. doi: 10.1002/jpen.2286
   PubMed Web of Science ®Google Scholar
• Zealand Pharma A/S. Acylated GLP-1/GLP-2 dual agonists. US2020297818A1. 2020.
   Google Scholar
• Heptares Therapeutics Limited. GLP receptor agonists. WO2021186166. 2021.
   Google Scholar
• Heptares Therapeutics Limited. Oral GLP receptor agonists. WO2021186169. 2021.
   Google Scholar
• Camilleri M. Gastrointestinal hormones and regulation of gastric emptying. Curr Opin Endocrinol Diabetes Obes. 2019 Feb;26(1):3–10. doi: 10.1097/MED.0000000000000448
   PubMedGoogle Scholar
• Zhou J, Martin RJ, Raggio AM, et al. The importance of GLP-1 and PYY in resistant starch’s effect on body fat in mice. Mol Nutr Food Res. 2015 May;59(5):1000–1003. doi: 10.1002/mnfr.201400904
   PubMed Web of Science ®Google Scholar
• Alhabeeb H, AlFaiz A, Kutbi E, et al. Gut hormones in health and obesity: the upcoming role of short chain fatty acids. Nutrients. 2021 Jan 31;13(2):481. doi: 10.3390/nu13020481
   PubMed Web of Science ®Google Scholar
• Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature. 2002 Aug 8;418(6898):650–654. doi: 10.1038/nature00887
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutica. Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof. CN112004822A. 2020.
   Google Scholar
• Guangxi Medical University Affiliated Tumour Hospital. GLP-1/Y2 receptor dual agonist and application thereof. CN115819619A. 2023.
   Google Scholar
• Guangxi Medical University Affiliated Tumour Hospital. GLP-1/Glucagon/Y-2 receptor triple agonist and application thereof. CN115960258A. 2023.
   Google Scholar
• Wei W, Dutchak PA, Wang X, et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3143–3148. doi: 10.1073/pnas.1200797109
   PubMed Web of Science ®Google Scholar
• Kharitonenkov A, DiMarchi R. Fibroblast growth factor 21 night watch: advances and uncertainties in the field. J Intern Med. 2017 Mar;281(3):233–246. doi: 10.1111/joim.12580
   PubMed Web of Science ®Google Scholar
• Sanofi. FGF21 compound/GLP-1R agonist combinations with optimized activity ratio. WO2018115401. 2018.
   Google Scholar
• Sanofi. FGF21 compound/GLP-1R agonist combinations with optimized activity ratio. WO2019243557. 2019.
   Google Scholar
• Zhejiang Doer Biologics Corporation. Multi-domain active protein for treating metabolic diseases. CN115109166A. 2022.
   Google Scholar
• Pharmaceutical formulations patent WO2021144476. 2021.
   Google Scholar
• Tsai VW, Macia L, Johnen H, et al. TGF-b superfamily cytokine MIC-1/GDF15 is a physiological appetite and body weight regulator. PLoS One. 2013;8(2):e55174. doi: 10.1371/journal.pone.0055174
   PubMed Web of Science ®Google Scholar
• Nipro Corporation. Method for manufacturing catheter, and catheter. WO2022145179. 2022.
   Google Scholar